Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
The purpose of the study is to compare time to progression and overall survival after treatment with Taxotere plus cisplatin versus cisplatin plus 5-FU (PF treatment group) in the first line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Head and Neck Neoplasms|Neoplasm Recurrence, Local|Neoplasm Metastasis
DRUG: docetaxel (XRP6976)|DRUG: cisplatin|DRUG: 5-fluorouracil (5-FU)
time to progression, up to 5 years
overall survival, overall response rate (complete response + partial response), duration of response, and time to treatment failure, up to 5 years
The purpose of the study is to compare time to progression and overall survival after treatment with Taxotere plus cisplatin versus cisplatin plus 5-FU (PF treatment group) in the first line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.